Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12 ® Lactobacillus rhamnosus LGG ® in colorectal cancer patients.

Michal Mego,Radoslav Danis,Jozef Chovanec,Silvia Jurisova,Branislav Bystricky,Stefan Porsok,Peter Konkolovsky,Vladimir Vaclav,Maria Wagnerova,Marian Streško,Bibiana Brezinova,Mária Rečková,Dagmar Sutekova,Natalia Pazderova,Mária Novisedlakova,Eva Zomborska,Sona Ciernikova,Daniela Svetlovska,Lubos Drgona

Frontiers in oncology（2023）

Cited 0|Views8

No score

Abstract

This study failed to achieve its primary endpoint, and results suggest a lack of benefit of administered probiotic formula for the prevention of irinotecan-induced diarrhea. However, subgroup analysis suggests a possible benefit in patients with colostomy.

Translated text

Key words

probiotic mixture,colorectal cancer,diarrhea,double-blind,placebo-controlled,irinotecan-induced

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined